| scholarly article | Q13442814 |
| P2093 | author name string | X Li | |
| P Coffino | |||
| P2860 | cites work | Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene | Q24298218 |
| Inhibition of p53 DNA binding by human papillomavirus E6 proteins | Q24317013 | ||
| The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 | Q24317677 | ||
| The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases | Q24319848 | ||
| Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells | Q24555806 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase | Q27860571 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription | Q28187745 | ||
| HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes | Q28254780 | ||
| p21 is a universal inhibitor of cyclin kinases | Q28257305 | ||
| The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots | Q72693767 | ||
| SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene | Q28281071 | ||
| p53 mutations in human cancers | Q28302973 | ||
| The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 | Q29547773 | ||
| A 26 S protease subunit that binds ubiquitin conjugates | Q29614362 | ||
| The ubiquitin system for protein degradation | Q29614385 | ||
| A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia | Q29615437 | ||
| T antigen is bound to a host protein in SY40-transformed cells | Q29618321 | ||
| Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins | Q33292223 | ||
| Analysis of a protein-binding domain of p53 | Q33292314 | ||
| Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product | Q33589833 | ||
| Monoclonal antibodies specific for simian virus 40 tumor antigens | Q34249232 | ||
| p53 functions as a cell cycle control protein in osteosarcomas | Q34254691 | ||
| Precise epitope mapping of the murine transformation-associated protein, p53. | Q35006968 | ||
| A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18 | Q35937193 | ||
| Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway | Q36648425 | ||
| Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. | Q36660357 | ||
| Use of the two-hybrid system to identify the domain of p53 involved in oligomerization | Q36783948 | ||
| The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes | Q36831207 | ||
| Characterization of primary human keratinocytes transformed by human papillomavirus type 18. | Q36868528 | ||
| Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. | Q36886337 | ||
| Post-Translational Regulation of the 54K Cellular Tumor Antigen in Normal and Transformed Cells | Q36966578 | ||
| Two Distinct Mechanisms Regulate the Levels of a Cellular Tumor Antigen, p53 | Q36980764 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein | Q38313694 | ||
| Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation | Q38332737 | ||
| The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. | Q40041446 | ||
| Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells | Q40237209 | ||
| Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis | Q40647696 | ||
| Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form | Q41210647 | ||
| Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. | Q41508377 | ||
| A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization | Q41612441 | ||
| Presence of a potent transcription activating sequence in the p53 protein | Q41724404 | ||
| The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif | Q41742127 | ||
| Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein | Q41987593 | ||
| Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papillomavirus type 16 DNA. | Q42817558 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. | Q44769248 | ||
| Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation | Q45037523 | ||
| p53 domains: identification and characterization of two autonomous DNA-binding regions. | Q52544476 | ||
| Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. | Q53503674 | ||
| Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. | Q54422442 | ||
| Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells | Q64381309 | ||
| The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain | Q72520479 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4509-4516 | |
| P577 | publication date | 1996-07-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation | |
| P478 | volume | 70 |
| Q34509620 | A Small Ribosomal Subunit (SSU) Processome Component, the Human U3 Protein 14A (hUTP14A) Binds p53 and Promotes p53 Degradation |
| Q33800021 | Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. |
| Q39153847 | An RNA Aptamer Targets the PDZ-Binding Motif of the HPV16 E6 Oncoprotein. |
| Q34251029 | Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas |
| Q33596688 | Association of intron and exon polymorphisms of p53 gene in Iranian patients with gastritis |
| Q30860353 | Cell-specific modulation of papovavirus replication by tumor suppressor protein p53 |
| Q36989890 | Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses |
| Q36478774 | Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal |
| Q37392961 | Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited |
| Q40103314 | Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. |
| Q47153289 | Delineation of the HPV11E6 and HPV18E6 Pathways in Initiating Cellular Transformation. |
| Q39948840 | E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation |
| Q28652354 | Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model |
| Q28360379 | HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation |
| Q33384291 | HPV E6, E6AP and cervical cancer |
| Q26770487 | HPV-p53-miR-34a axis in HPV-associated cancers |
| Q93010911 | Human Papillomavirus 11 Early Protein E6 Activates Autophagy by Repressing AKT/mTOR and Erk/mTOR |
| Q34980270 | Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis |
| Q37769103 | Human papillomavirus oncoproteins: pathways to transformation |
| Q24551145 | Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase |
| Q36897152 | In GFP with high risk HPV-18E6 fusion protein expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently phosphorylated at multiple sites |
| Q35685208 | Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides |
| Q33883972 | Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. |
| Q49676592 | Low risk HPV-6E6 induces apoptosis in bone marrow-derived dendritic cells |
| Q41810748 | Low risk HPV-E6 traps p53 in the cytoplasm and induces p53-dependent apoptosis |
| Q39147256 | Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes |
| Q36303426 | Molecular mechanisms of human papillomavirus-induced carcinogenesis. |
| Q33649218 | Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells |
| Q35870606 | Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. |
| Q30410553 | Papillomavirus E6 oncoproteins |
| Q37350446 | Papillomavirus E6 proteins |
| Q92715593 | Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System |
| Q36527456 | Posttranslational phosphorylation of mutant p53 protein in tumor development |
| Q34064334 | Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain |
| Q55982769 | Recurrent respiratory papillomatosis |
| Q64992613 | Regulating the human HECT E3 ligases. |
| Q40589896 | Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. |
| Q35107717 | Small molecule inhibitors of human papillomavirus protein - protein interactions |
| Q27678346 | Solution Structure Analysis of the HPV16 E6 Oncoprotein Reveals a Self-Association Mechanism Required for E6-Mediated Degradation of p53 |
| Q30277715 | Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. |
| Q35192650 | Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance |
| Q42727197 | The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2. |
| Q36064347 | Transcriptomic analyses of genes differentially expressed by high-risk and low-risk human papilloma virus E6 oncoproteins |
| Q37343693 | Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. |
| Q35354212 | Ubiquitin-independent proteasomal degradation during oncogenic viral infections |
| Q39576424 | Viral oncoproteins discriminate between p53 and the p53 homolog p73. |
| Q39460833 | c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination |
| Q39579847 | p53 protein is a suppressor of papillomavirus DNA amplificational replication |
Search more.